Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Rasche

Showing results (141-150 of 170) with videos related to

Pageof 17
Sort By:
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood|June 11, 2021
Cereblon enhancer methylation and IMiD resistance in multiple myelomaLarissa Haertle, Santiago Barrio, Umair Munawar, et al.
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple MyelomaLarissa Haertle, Santiago Barrio, Umair Munawar, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Vaccines|November 26, 2024
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple MyelomaKhalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, et al.
Leukemia|September 10, 2025
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myelomaSven Neubert, Umair Munawar, Julia Mersi, et al.
Haematologica|May 20, 2017
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtypeCarolina Schinke, Antje Hoering, Hongwei Wang, et al.
Blood Cancer Discovery|November 14, 2025
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironmentAnjana Anilkumar Sithara, Veronika Kapustova, David Zihala, et al.
Nature Medicine|July 6, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Pageof 17

Showing results (141-150 of 170) with videos related to

Sort By:
Pageof 17
Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.
Blood|June 11, 2021
Cereblon enhancer methylation and IMiD resistance in multiple myelomaLarissa Haertle, Santiago Barrio, Umair Munawar, et al.
Blood|August 13, 2016
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myelomaNiels Weinhold, Cody Ashby, Leo Rasche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple MyelomaLarissa Haertle, Santiago Barrio, Umair Munawar, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Vaccines|November 26, 2024
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple MyelomaKhalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, et al.
Leukemia|September 10, 2025
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myelomaSven Neubert, Umair Munawar, Julia Mersi, et al.
Haematologica|May 20, 2017
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtypeCarolina Schinke, Antje Hoering, Hongwei Wang, et al.
Blood Cancer Discovery|November 14, 2025
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironmentAnjana Anilkumar Sithara, Veronika Kapustova, David Zihala, et al.
Nature Medicine|July 6, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Pageof 17